Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1985 1
1987 1
1988 2
1989 1
1990 1
1991 2
1992 1
1993 3
1994 1
1995 4
1998 3
1999 2
2000 3
2001 1
2002 9
2003 5
2004 5
2005 2
2006 6
2007 6
2008 4
2009 12
2010 14
2011 14
2012 14
2013 18
2014 25
2015 21
2016 20
2017 31
2018 34
2019 27
2020 30
2021 42
2022 44
2023 52
2024 38
2025 44
2026 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

502 results

Results by year

Citations

7 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Diagnosis of mast cell activation syndrome: a global "consensus-2".
Afrin LB, Ackerley MB, Bluestein LS, Brewer JH, Brook JB, Buchanan AD, Cuni JR, Davey WP, Dempsey TT, Dorff SR, Dubravec MS, Guggenheim AG, Hindman KJ, Hoffman B, Kaufman DL, Kratzer SJ, Lee TM, Marantz MS, Maxwell AJ, McCann KK, McKee DL, Menk Otto L, Pace LA, Perkins DD, Radovsky L, Raleigh MS, Rapaport SA, Reinhold EJ, Renneker ML, Robinson WA, Roland AM, Rosenbloom ES, Rowe PC, Ruhoy IS, Saperstein DS, Schlosser DA, Schofield JR, Settle JE, Weinstock LB, Wengenroth M, Westaway M, Xi SC, Molderings GJ. Afrin LB, et al. Diagnosis (Berl). 2020 Apr 22;8(2):137-152. doi: 10.1515/dx-2020-0005. Print 2021 May 26. Diagnosis (Berl). 2020. PMID: 32324159 Review.
The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of "mast cell …
The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), with …
Mast cell activation syndrome: Current understanding and research needs.
Castells M, Giannetti MP, Hamilton MJ, Novak P, Pozdnyakova O, Nicoloro-SantaBarbara J, Jennings SV, Francomano C, Kim B, Glover SC, Galli SJ, Maitland A, White A, Abonia JP, Slee V, Valent P, Butterfield JH, Carter M, Metcalfe DD, Akin C, Lyons JJ, Togias A, Wheatley L, Milner JD. Castells M, et al. J Allergy Clin Immunol. 2024 Aug;154(2):255-263. doi: 10.1016/j.jaci.2024.05.025. Epub 2024 Jun 6. J Allergy Clin Immunol. 2024. PMID: 38851398 Free PMC article. Review.
Mast cell activation syndrome (MCAS) is a term applied to several clinical entities that have gained increased attention from patients and medical providers. Although several descriptive publications about MCAS exist, there are many gaps in knowledge, …
Mast cell activation syndrome (MCAS) is a term applied to several clinical entities that have gained increased a …
Mast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management.
Hamilton MJ. Hamilton MJ. Curr Gastroenterol Rep. 2024 Apr;26(4):107-114. doi: 10.1007/s11894-024-00924-w. Epub 2024 Feb 14. Curr Gastroenterol Rep. 2024. PMID: 38353900 Review.
PURPOSE OF REVIEW: Mast cell activation syndrome (MCAS) is a clinical disorder that may explain irritable bowel syndrome (IBS) type symptoms as well as other allergic symptoms experienced by an individual. ...RECENT FINDINGS: Although biomarkers …
PURPOSE OF REVIEW: Mast cell activation syndrome (MCAS) is a clinical disorder that may explain irritable bowel …
Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis.
Weiler CR. Weiler CR. J Allergy Clin Immunol Pract. 2020 Feb;8(2):498-506. doi: 10.1016/j.jaip.2019.08.022. Epub 2019 Aug 27. J Allergy Clin Immunol Pract. 2020. PMID: 31470118 Review.
The current consensus diagnostic criteria for mast cell activation syndrome(s) (MCAS[s]) were first established in 2012 and updated in 2019. This diagnosis has been attached to multiple medical conditions not intended as part of the diagnosis …
The current consensus diagnostic criteria for mast cell activation syndrome(s) (MCAS[s]) were first established …
Mast Cell Activation Syndrome: A Primer for the Gastroenterologist.
Weinstock LB, Pace LA, Rezaie A, Afrin LB, Molderings GJ. Weinstock LB, et al. Dig Dis Sci. 2021 Apr;66(4):965-982. doi: 10.1007/s10620-020-06264-9. Epub 2020 Apr 23. Dig Dis Sci. 2021. PMID: 32328892 Review.
Mast cell activation syndrome is thought to be a common, yet under-recognized, chronic multi-system disorder caused by inappropriate mast cell activation. ...In this article, we review mast cell function and dysfuncti …
Mast cell activation syndrome is thought to be a common, yet under-recognized, chronic multi-system disorder cau …
Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
Matito A, Escribese MM, Longo N, Mayorga C, Luengo-Sánchez O, Pérez-Gordo M, Matheu V, Labrador-Horrillo M, Pascal M, Seoane-Reula ME; Comité de Inmunología de la Sociedad Española de Alergología e Inmunología Clínica (SEAIC). Matito A, et al. J Investig Allergol Clin Immunol. 2021 Dec 21;31(6):461-470. doi: 10.18176/jiaci.0675. Epub 2020 Feb 5. J Investig Allergol Clin Immunol. 2021. PMID: 33541851 Free article. Review.
The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria: (1) typical clinical signs and symptoms of acute, recurrent (episodic), and systemic mast cell activation (MCA); (2) increase in tryptase level …
The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria: (1) typical clinical sign …
AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management.
Weiler CR, Austen KF, Akin C, Barkoff MS, Bernstein JA, Bonadonna P, Butterfield JH, Carter M, Fox CC, Maitland A, Pongdee T, Mustafa SS, Ravi A, Tobin MC, Vliagoftis H, Schwartz LB. Weiler CR, et al. J Allergy Clin Immunol. 2019 Oct;144(4):883-896. doi: 10.1016/j.jaci.2019.08.023. Epub 2019 Aug 30. J Allergy Clin Immunol. 2019. PMID: 31476322
Our current recommendations for diagnosing and treating primary mast cell (MC) activation syndrome make use of the latest studies and consensus guidelines for clinically recognizing systemic anaphylaxis in real time, regardless of whether allerg …
Our current recommendations for diagnosing and treating primary mast cell (MC) activation syndrome make u …
Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities.
Blitshteyn S. Blitshteyn S. Curr Neurol Neurosci Rep. 2023 Nov;23(11):769-776. doi: 10.1007/s11910-023-01307-w. Epub 2023 Oct 17. Curr Neurol Neurosci Rep. 2023. PMID: 37847487 Review.
The most common autonomic disorders are postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope (NCS), and orthostatic hypotension (OH), which may be encountered in clinical practice as part of a triad of dysautonomia, hypermobility spectrum disorders (H …
The most common autonomic disorders are postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope (NCS), and orthost …
The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS).
Kucharik AH, Chang C. Kucharik AH, et al. Clin Rev Allergy Immunol. 2020 Jun;58(3):273-297. doi: 10.1007/s12016-019-08755-8. Clin Rev Allergy Immunol. 2020. PMID: 31267471 Review.
In recent years, an association between hypermobile Ehlers-Danlos syndrome (hEDS), mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS) has garnered attention and patients are increasingly presenting …
In recent years, an association between hypermobile Ehlers-Danlos syndrome (hEDS), mast cell activation syndr …
Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options.
Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Afrin LB, et al. Ann Med. 2016;48(3):190-201. doi: 10.3109/07853890.2016.1161231. Epub 2016 Mar 25. Ann Med. 2016. PMID: 27012973 Review.
Mast cell (MC) disease has long been thought to be just the rare disease of mastocytosis (in various forms, principally cutaneous and systemic), with aberrant MC mediator release at symptomatic levels due to neoplastic MC proliferation. Recent discoveries now show a …
Mast cell (MC) disease has long been thought to be just the rare disease of mastocytosis (in various forms, principally cutane …
502 results